: 20530502  [PubMed - indexed for MEDLINE]954. J Card Surg. 2010 Jul;25(4):462-71. doi: 10.1111/j.1540-8191.2010.01050.x. Epub2010 May 30.Destination therapy: patient selection and current outcomes.Lietz K(1).Author information: (1)Center for Advanced Heart Failure and Transplantation, Yale University School of Medicine, New Haven, Connecticut 06520-8017, USA. Katherine.Lietz@yale.eduLong-term left-ventricular assist device (LVAD) support as destination therapy(DT) is a promising new alternative for the growing population of patients withadvanced heart failure. In this article, we summarize the clinical trials thatled to the approval of LVAD use as DT in the US national policies regulatingcandidate selection and DT center accreditation. We review current guidelines forcandidate selection, clinical tools to assess candidate operative risk, andoutcomes of DT.